Serena Lavorgna - Concepedia

Author

Serena Lavorgna

University of Rome Tor Vergata ORCID

Also Known As

Lavorgna Serena, S Lavorgna, S. Lavorgna, Serena Lavorgna

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

University of Rome Tor Vergata Fondazione Santa Lucia Sapienza University of Rome Fondazione Gimema Onlus Policlinico Tor Vergata

About

Serena Lavorgna is an author at University of Rome Tor Vergata specializing in medicine, molecular diagnostics, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	579
2	Cell Biology	7	7	381
3	Engineering	3	3	114
4	Health Sciences	1	1	128
5	Cellular Physiology	1	1	82

Serena Lavorgna

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia Adriano Venditti, Alfonso Piciocchi, Anna Candoni, Blood	2019	208
Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia Francesco Buccisano, Luca Maurillo, Alessandra Spagnoli, Blood	2010	131
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia Nélida I. Noguera, Emanuele Ammatuna, D Zangrilli, Leukemia Hematological MalignancyFlt3-itd MutationsCapillary ElectrophoresisLaboratory HematologyMedicine	2005	128
A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes Silvia Careccia, Sara Mainardi, Andrea Pelosi, Oncogene Systems BiologyDevelopmental BiologyEngineeringCell DivisionMedicine	2009	82
A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies <i>FLT3</i> -Mutated Clones in Acute Myeloid Leukemia Daniela F. Angelini, Tiziana Ottone, Gisella Guerrera, Clinical Cancer Research	2015	81
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy Laura Cicconi, Mariadomenica Divona, Claudia Ciardi, Leukemia Pml–rarα KineticsHematological MalignancyMedicineMixed-phenotype Acute LeukemiaImmunology	2016	80
miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia Andrea Pelosi, Silvia Careccia, Valentina Lulli, Oncogene Hematological MalignancyAcute Myeloid LeukemiaHematologyMicrorna DetectionMedicine	2012	67
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib Isabella Faraoni, Mirco Compagnone, Serena Lavorgna, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease Hematological MalignancyTumor BiologyParp Inhibitor OlaparibOncologyMedicine	2014	61
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial Maria Teresa Voso, Richard A. Larson, Dan Jones, Blood Advances	2020	56
The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia Anna Giulia Sanarico, Chiara Ronchini, Anna Cleta Croce, Leukemia	2017	47

Page 1